Understanding the Value of Response and Early Tumour Shrinkage (ETS) in Pts with Wt kras MCRC Treated with Panitumumab (P) Plus Folfox (F)

Jean‐Yves Douillard(Integrated Oncology (United States)), R. Sidhu(Amgen (United States)), Salvatore Siena(University of Milan), Josep Tabernero(Deaconess Hospital), Chris Davison(Amgen (United Kingdom)), Stephan Braun(Amgen (Switzerland)), Marc Peeters(University of Antwerp)
Annals of Oncology
September 1, 2012
Cited by 2


Related Papers